Wenliang Chen | Clinical medicine | Best Researcher Award

Published on by Academic Awards

Assoc. Prof. Dr. Wenliang Chen | Clinical medicine | Best Researcher Award

Assoc. Prof. Dr. Wenliang Chen, Shanxi Medical University, China

Dr. Wenliang Chen completed his Bachelor’s degree in Clinical Medicine at Shanxi Medical University in 1996. He further pursued a Master’s degree in General Surgery at the same institution, graduating in 2002. To deepen his expertise, he obtained a Doctor of Medicine in General Surgery from the prestigious Chinese PLA General Hospital in 2023. His academic journey reflects a steadfast commitment to advancing surgical knowledge and practices, supported by specialized training in Surgical ICU and Gastrointestinal Surgery at leading hospitals in China and the USA.

Publication Profile

Orcid

Education 🎓

Dr. Wenliang Chen completed his Bachelor’s degree in Clinical Medicine at Shanxi Medical University in 1996. He further pursued a Master’s degree in General Surgery at the same institution, graduating in 2002. To deepen his expertise, he obtained a Doctor of Medicine in General Surgery from the prestigious Chinese PLA General Hospital in 2023. His academic journey reflects a steadfast commitment to advancing surgical knowledge and practices, supported by specialized training in Surgical ICU and Gastrointestinal Surgery at leading hospitals in China and the USA.

Experience 💼

Dr. Chen’s career spans more than 20 years, beginning as a General Surgeon at the Second Hospital of Shanxi Medical University. His experience includes advanced surgical training at Beijing Chaoyang Hospital and Peking University People’s Hospital. Additionally, he gained international insights as a Visiting Scholar at Duke University Medical Center and The Ohio State University. Since 2015, he has been a prominent figure in gastrointestinal and minimally invasive surgeries. His dedication to patient care and academic mentorship has greatly contributed to the institution’s medical excellence.

Awards and Honors 🏆

Assoc. Prof. Dr. Wenliang Chen has earned numerous accolades for his contributions to the field of surgery. His pioneering efforts in obesity and diabetes surgery in Shanxi Province and his successful laparoscopic Nissen fundoplication for gastroesophageal reflux disease have established him as a surgical innovator. Furthermore, his active roles in national and provincial medical committees, including the Colorectal Cancer Committee and the Gastrointestinal Surgery Committee, exemplify his leadership and dedication to medical advancement.

Research Focus 🔎

Dr. Chen’s research primarily focuses on the diagnosis and surgical treatment of gastrointestinal diseases. He has led significant studies, notably as Principal Investigator on the regulatory mechanism of LncRNA PVT1 in gastric cancer proliferation and invasion. His interest in minimally invasive surgeries has led to advancements in laparoscopic techniques, benefiting patient recovery and surgical outcomes. His dedication to translational research has strengthened the clinical application of innovative treatments, contributing to the advancement of gastrointestinal oncology and metabolic disease management.

Publication Top Notes

📄 Innovative Approaches to Managing Postoperative Complications in Laparoscopic Sleeve Gastrectomy: A Scoping Review (2024) | 🏛 Journal of Laparoendoscopic & Advanced Surgical Techniques. Part A | 🔗 DOI: 10.1089/lap.2024.0227

📄 Oxidative stress-related patterns determination for establishment of prognostic models, and characteristics of tumor microenvironment infiltration (2022) | 🏛 Frontiers in Surgery | 🔗 DOI: 10.3389/fsurg.2022.1013794

📄 Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer (2022) | 🏛 Frontiers in Immunology | 🔗 DOI: 10.3389/fimmu.2022.962056

📄 Efficacy and safety of over-the-scope clips for colorectal leaks and fistulas: a pooled analysis (2022) | 🏛 Minimally Invasive Therapy & Allied Technologies | 🔗 DOI: 10.1080/13645706.2021.2010218

📄 LncRNA SNHG6 inhibits autophagy of gastric carcinoma cells via PI3K/AKT/mTOR signaling pathway (2022) | 🏛 American Journal of Translational Research | 🔗 PMID: 35702105

📄 The Role of lncRNA PVT1 and hsa-miR-30a-3p in the Development of Gastric Cancer (2022) | 🏛 Annals of Clinical and Laboratory Science | 🔗 PMID: 35414508

📄 Laparoscopy for Hepatolithiasis: Biliary Duct Exploration with Primary Closure Versus T-Tube Drainage (2020) | 🏛 Journal of Laparoendoscopic & Advanced Surgical Techniques | 🔗 DOI: 10.1089/lap.2020.0081

📄 A Comparison of the Relative Safety and Efficacy of Laparoscopic Choledochotomy with Primary Closure and Endoscopic Treatment for Bile Duct Stones in Patients with Cholelithiasis (2020) | 🏛 Journal of Laparoendoscopic & Advanced Surgical Techniques | 🔗 DOI: 10.1089/lap.2019.0775

 

khadijeh kalanfarmanfarma | Health Professions Award | Best Researcher Award

Published on by Academic Awards

Dr. khadijeh kalanfarmanfarma | Health Professions Award | Best Researcher Award

Dr. khadijeh kalanfarmanfarma, Kashan University of Medical Sciences, Kashan, Iran

Dr. Khadijeh Kalan Farmanfarma (born April 24, 1978) holds a PhD in Epidemiology and an M.Sc. in Health Education and Promotion. She has been recognized as a top researcher at both the national and university levels, notably at Zahedan University of Medical Sciences. Dr. Farmanfarma has contributed to over 20 high-impact publications, focusing on cancer epidemiology, metabolic syndrome, and public health. She is also a co-author of an eBook on the Renin-Angiotensin System and its role in diseases. Her research has earned her awards and recognition both nationally and internationally. 📚🌍🔬

 

Publication profile

Academic Background 🧠

Dr. Khadijeh Kalan Farmanfarma holds a PhD in Epidemiology and an M.Sc. in Health Education and Health Promotion. Her solid academic foundation is supported by multiple recognitions at the doctoral and master’s levels. Her focus on epidemiological research is crucial, particularly during global health challenges like COVID-19.

Research Contributions 📚

Dr. Farmanfarma has an impressive body of work, with more than 25 published research articles across Q1 to Q3 journals. Some highlights include:

COVID-19 Research: Her studies on the impact of COVID-19, especially on domestic violence and illness anxiety, show her commitment to addressing emerging public health issues.

Metabolic Syndrome & Cancer Epidemiology: Dr. Farmanfarma has published meta-analyses on metabolic syndrome and various cancers, which have gained significant attention in high-impact journals like Diabetes & Metabolic Syndrome: Clinical Research & Reviews (IF: 10.0, Q1).

Chronic Diseases & Breast Cancer Prevention: Her focus on chronic diseases and breast cancer prevention demonstrates her dedication to improving population health.

Recognitions 🏆

Dr. Farmanfarma’s accolades include being named the Top National Researcher and Top Researcher at Zahedan University of Medical Sciences multiple times, which speaks to her consistent excellence in research.

Publication Top Notes 

  • 📚 Prevalence of metabolic syndrome in Middle-East countries: Meta-analysis of cross-sectional studies – Cited by: 248 (2018)
  • 📚 Prevalence of metabolic syndrome in Iran: A meta-analysis of 69 studies – Cited by: 149 (2019)
  • 🧠 Brain cancer in the world: An epidemiological review – Cited by: 79 (2019)
  • 🎗️ Improving Breast Cancer Preventive Behavior among Female Medical Staff: Educational Intervention – Cited by: 59 (2014)
  • 📊 Epidemiologic study of gastric cancer in Iran: A systematic review – Cited by: 51 (2020)
  • 📈 Prevalence of type 2 diabetes in Middle-East: Systematic review & meta-analysis – Cited by: 47 (2020)
  • 🎗️ Effect of education on preventive behaviors of breast cancer in female teachers – Cited by: 35 (2014)
  • 🩺 Study of breast cancer knowledge, attitude, and preventive behaviors in Yazd, Iran – Cited by: 22 (2017)
  • 📊 Prevalence and trend of metabolic syndrome in South-East Iran – Cited by: 21 (2020)
  • 🧬 Testicular cancer in the world: An epidemiological review – Cited by: 20 (2018)

Conclusion 📝

With her extensive research output, recognitions, and focus on significant public health issues, Dr. Khadijeh Kalan Farmanfarma is a strong candidate for the Research for Best Researcher Award. Her diverse and impactful research contributions in epidemiology, particularly in chronic diseases and cancer, reflect a distinguished career deserving of recognition.

 

 

Rainer Pooth | Medicine and Dentistry Award | Best Innovation Award

Published on by Academic Awards

Dr. Rainer Pooth | Medicine and Dentistry Award | Best Innovation Award

Dr. Rainer Pooth, ICAAN GmbH, Germany

Based on the information provided, Dr. Rainer Pooth appears to be a highly suitable candidate for the “Research for Best Innovation Award” in the pharmaceutical and medical industry. Here’s an assessment of his qualifications:

Publication profile

Professional Experience & Leadership

Dr. Pooth has over 20 years of experience in the global pharmaceutical and medical industry, with a strong track record of leadership in multidisciplinary teams at both global and affiliate levels. His roles as Managing Director, Global Head of Medical/Scientific Affairs, and Head of Global Clinical Development demonstrate his ability to lead and innovate in complex, highly regulated environments. His strategic input in global R&D programs, project management, and regulatory affairs underscores his expertise in driving innovation and ensuring successful product development.

Achievements & Expertise

Dr. Pooth’s achievements include multiple approvals of medicinal products and medical devices across key global markets such as the EU, US, Australia, and Asia. He holds more than 35 patents, with a significant portion becoming commercially relevant, highlighting his innovative contributions to the field. His extensive publication record, including over 50 publications in international journals and books, as well as his role as an invited speaker at major scientific congresses, further cements his reputation as a leader in pharmaceutical research and innovation.

Global Impact & Collaboration

Dr. Pooth’s global network of experts and key opinion leaders, along with his experience in managing international submission teams and regulatory interactions, illustrates his ability to navigate and influence the global pharmaceutical landscape. His leadership in directing high-level global teams and managing collaborations with regulatory authorities and contract research organizations (CROs) demonstrates his capability to bring innovative products to market successfully.

Publication Top Notes

  • “Treatment of Refractory Cardiac Arrest by Controlled Reperfusion of the Whole Body” – A study exploring CARL in a multicenter setting, highlighting its impact on refractory cardiac arrest patients (2023).
  • “The Impact of Head Position on Neurological and Histopathological Outcome Following CARL” – Investigates how head positioning affects outcomes in a pig model during CARL (2023).
  • “Extracorporeal Cardiopulmonary Resuscitation—Evidence and Implications” – Discusses ECPR’s evidence base and its clinical implications (2023).
  • “Effects of Prolonged Serum Calcium Suppression during ECPR in Pigs” – Examines the effects of serum calcium suppression during ECPR, showing implications for treatment strategies (2023).
  • “Limiting Calcium Overload after Cardiac Arrest” – Focuses on the role of albumin in reducing calcium overload during CARL (2023).
  • “Pervasive Platelet Secretion Defects in SARS-CoV-2 Patients” – Analyzes platelet defects in COVID-19 patients and their potential implications for treatment (2023).
  • “CARL – Controlled Reperfusion of the Whole Body” – A book detailing the CARL procedure, providing a comprehensive resource for clinicians (2022).
  • “Observational Study on Implications of the COVID-19-Pandemic for Cardiopulmonary Resuscitation” – Examines the pandemic’s impact on resuscitation practices, offering valuable insights (2022).
  • “Monitoring Mitochondrial Partial Oxygen Pressure During Cardiac Arrest and ECPR” – A pilot study exploring mitochondrial oxygen monitoring during cardiac arrest in a pig model (2021).
  • “Brain Vulnerability and Viability after Ischaemia” – A review on the neurological outcomes following ischemic events, highlighting vulnerabilities and potential treatment avenues (2021).

Conclusion

Dr. Pooth’s extensive experience, significant contributions to the development and approval of innovative pharmaceutical products, and his leadership in global research and development make him a strong candidate for the “Research for Best Innovation Award.” His work has had a substantial impact on multiple therapeutic areas, including dermatology, immunology, aesthetic medicine, oncology, and neurology, making him well-deserving of recognition in this prestigious category.